Pfizer On Lung Cancer: "We Need To Have Single-Agent Avelumab"

After announcing a setback for the PD-L1 inhibitor Bavencio (avelumab) in first-line non-small cell lung cancer that will push data out to 2019, Pfizer Inc.'s Oncology President Liz Barrett said the company believes it is still important to get avelumab approved as a single agent for the indication.

"We feel like we need to have single agent avelumab approved in lung cancer," she said. "We need to demonstrate the value of avelumab in that setting." Barrett made the...